Cerebrospinal fluid catecholamines levels in Alzheimer's disease, frontotemporal dementia, and normal controls [0.03%]
阿尔茨海默病、额颞叶痴呆和正常对照者的脑脊液儿茶酚胺水平
Isabel Portela Moreira,Paula Serrão,Lucinda Sequeira et al.
Isabel Portela Moreira et al.
Aims: Catecholamine analysis and studies to modulate dopamine and norepinephrine in dementia have had contradictory results. We aimed to analyze the cerebrospinal fluid (CSF) levels of L-DOPA, dopamine, and norepinephrine...
Geographic distribution of amyotrophic lateral sclerosis-related genes: a systematic review [0.03%]
肌萎缩侧索硬化相关基因的地理分布：系统性综述
Beliu García-Parra,Josep M Guiu,Mónica Povedano et al.
Beliu García-Parra et al.
Introduction: Amyotrophic lateral sclerosis (ALS) is a rare motor neuron disease. There is no effective treatment, but disease-modifying therapies do exist. Objective. To identify the geographical distribution of ALS-rela...
Neuroprotective effects of ivermectin on Alzheimer's model induced by streptozotocin in rats [0.03%]
伊维菌素对链脲佐菌素诱导的阿尔兹海默症大鼠模型的神经保护作用
Neda Farajpour,Hamid Soraya
Neda Farajpour
Background: Alzheimer's disease is a neurodegenerative condition characterized by memory deficits and cognitive decline. Ivermectin, an antiparasitic agent, has shown neuroprotective effects. The present study was conduct...
Intravenous vs intrathecal transplantation of allogeneic GMP/GCP compliant Wharton's jelly mesenchymal stromal cells in ALS patients: a phase I study [0.03%]
用于肌萎缩侧索硬化患者的同种异体GMP / GCP规范的惠氏凝胶基质细胞移植的静脉注射与腰椎给药相比较：I期临床试验
Shahedeh Karimi,Azadeh Ghaheri,Hoda Madani et al.
Shahedeh Karimi et al.
Introduction: There are a few therapeutic approaches for Amyotrophic Lateral Sclerosis (ALS) which can only slow down or stop the disease progression for a limited period of time. Since it has been proven that Mesenchymal...
Real-world safety and tolerability of intravenous edaravone in patients with amyotrophic lateral sclerosis [0.03%]
特发性肺纤维化患者静脉注射依达拉奉的真实世界安全性及耐受性研究
Agessandro Abrahao,Polina Da Silva,Malgorzata Ciepielewska et al.
Agessandro Abrahao et al.
Aims: This retrospective cohort study describes real-world safety and tolerability outcomes in United States-based edaravone-treated patients with ALS. Pa...
Therapeutic strategies for Huntington's disease: current approaches and future direction [0.03%]
亨廷顿舞蹈症的治疗策略：当前方法与未来方向
Mehak Gulzar,Sana Kauser,Sumaiya Khan et al.
Mehak Gulzar et al.
Huntington's disease (HD) is an autosomal, progressive, dominant inherited neurological disorder characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. HD is caused by abnormal expansion of trinucleotide CAG in exo...
You look at life through a different lens: a phenomenological study of living with amyotrophic lateral sclerosis [0.03%]
不一样的视角看人生——失神经症的质性研究
Katherine Hope Morgan,Katherine Havranek,Chelsea Horn et al.
Katherine Hope Morgan et al.
Aims: Amyotrophic lateral sclerosis (ALS) is a motor neuron disease that progresses without periods of remission; few live more than five years beyond diagnosis. In this study we investigated the lived experiences of peop...
Tremor management strategies in Parkinson's disease: optimizing patient care [0.03%]
帕金森病的震颤管理策略：优化患者护理
Nicola Pavese,David Ledingham
Nicola Pavese
Along with bradykinesia and rigidity, tremor is one of the cardinal motor symptoms of Parkinson's disease (PD), often the first symptom to be noticed by the patient and their relatives. While bradykinesia and rigidity usually respond to dop...
Voice fundamental characteristics in Parkinson's disease: a case-control study of the Moroccan population [0.03%]
帕金森病患者发声的固有特征：摩洛哥人群的病例对照研究
D Khadri,E M Mahir,N Ouattassi et al.
D Khadri et al.
Parkinson's Disease (PD) is the second most common neurodegenerative disorder. Hypokinetic dysarthria, a motor speech disorder affects approximately 90% of PD patients. In Morocco, linguistic features of Moroccan Arabic may influence how vo...
Sleep disorders across the parkinsonism continuum: a typical example of geriatric complexity [0.03%]
帕金森病睡眠障碍：老龄化复杂性的典型案例
Marco Salvi,Fulvio Lauretani,Irene Zucchini et al.
Marco Salvi et al.